Technical Analysis for ONTX - Onconova Therapeutics, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Up | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
20 DMA Support | Bullish | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
MACD Bearish Signal Line Cross | Bearish | 4.52% | |
20 DMA Support | Bullish | 4.52% | |
1,2,3 Pullback Bullish | Bullish Swing Setup | 4.52% | |
Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 4.52% | |
Earnings Movers | Other | 4.52% | |
Wide Bands | Range Expansion | 4.52% | |
Earnings Movers | Other | -3.61% | |
Wide Bands | Range Expansion | -3.61% |
Alert | Time |
---|---|
10 DMA Resistance | about 8 hours ago |
Non-ADX 1,2,3,4 Pullback Entry | about 9 hours ago |
1,2,3, Pullback Entry | about 9 hours ago |
Rose Above Previous Day's High | about 9 hours ago |
Rose Above 10 DMA | about 9 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 03/14/2024
Onconova Therapeutics, Inc. Description
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drug candidates to treat cancer. Its products include Rigosertib intravenous (IV) that is in Phase III trials for higher risk myelodysplastic syndromes (MDS); Rigosertib Oral, which is Phase II clinical trials for patients with transfusion-dependent lower risk MDS and in patients with head and neck cancers; and Rigosertib IV, a combination therapy with gemcitabine in a Phase III clinical trials for the treatment of patients with metastatic pancreatic cancer. The company's products also comprise ON 013105 that is in Phase I clinical trials to treat various lymphomas and leukemias; and Recilisib, a molecule with radiation protection properties has completed four Phase I clinical trials. In addition, its preclinical products consist of ON 1231320, an inhibitor of polo-like kinase 2; ON 123300, an inhibitor of the cell cycle and cancer cell metabolism; ON 108600, an inhibitor of cyclin-dependent kinase 9 and casein kinase 2; ON 044580, a dual inhibitor of janus kinase 2 and Bcr-Abl kinase; ON 24 series of compounds that are oral anti-tubulin agents; and ON 146 series, which are selective inhibitors of PI3K alpha/delta isoforms. The company was founded in 1998 and is headquartered in Newtown, Pennsylvania.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Organic Compounds Chemical Compounds Lymphoma Radiation Pancreatic Cancer Leukemia Protein Kinase Inhibitor Cancer Cell Metabolism Myelodysplastic Syndrome Syndromes Head And Neck Cancer Pyridines Bemcentinib Cell Cycle Gemcitabine Kinase Tyrosine Kinase Inhibitors Combination Therapy Janus Kinase Piperazines Clinical Products Preclinical Products
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 1.45 |
52 Week Low | 0.5509 |
Average Volume | 71,434 |
200-Day Moving Average | 0.82 |
50-Day Moving Average | 0.75 |
20-Day Moving Average | 0.84 |
10-Day Moving Average | 0.91 |
Average True Range | 0.07 |
RSI (14) | 55.75 |
ADX | 46.66 |
+DI | 25.59 |
-DI | 12.10 |
Chandelier Exit (Long, 3 ATRs) | 0.84 |
Chandelier Exit (Short, 3 ATRs) | 0.86 |
Upper Bollinger Bands | 1.03 |
Lower Bollinger Band | 0.65 |
Percent B (%b) | 0.58 |
BandWidth | 45.22 |
MACD Line | 0.05 |
MACD Signal Line | 0.05 |
MACD Histogram | -0.0044 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 1.05 | ||||
Resistance 3 (R3) | 1.05 | 1.00 | 1.02 | ||
Resistance 2 (R2) | 1.00 | 0.96 | 1.00 | 1.01 | |
Resistance 1 (R1) | 0.94 | 0.93 | 0.97 | 0.93 | 1.00 |
Pivot Point | 0.88 | 0.88 | 0.90 | 0.88 | 0.88 |
Support 1 (S1) | 0.82 | 0.84 | 0.85 | 0.81 | 0.74 |
Support 2 (S2) | 0.77 | 0.81 | 0.76 | 0.73 | |
Support 3 (S3) | 0.70 | 0.77 | 0.72 | ||
Support 4 (S4) | 0.69 |